San Diego, May 20, 2019/PRNewswire /--
Early studies using blood
Methylation-based DNA markers identified through long-term collaboration between accurate science and Mayo Clinic show the potential for detecting 92% sensitivity and 92% specificity of the most common type of pancreatic cancer.
The researchers made the discovery during Digestive Disease Week (DDW)
2019, the largest international gathering of physicians, researchers and scholars in the areas of digestive medicine, liver disease, endoscopy and stomach surgery.
Kevin Conroy, chairman and CEO of precision science, said: "These pancreatic cancer data demonstrate the power of our collaboration with the Mayo Clinic's marker discovery, which is driving our product line . ".
"Our goal is to set a minimum.
Invasive markers of a disease that, when there are fewer treatment options, is often undiscovered until it progresses to an advanced stage.
The third is pancreatic cancer.
The main causes of cancer
Related deaths in the United States.
According to the American Cancer Society, half of all patients with pancreatic cancer are in five.
The average annual survival rate is only 3%.
There is no major guideline to recommend routine screening for patients at average risk, as current testing options do not show a reduction in the risk of death for patients.
Lead author and psychiatrist Shounak Majumder at Mayo Clinic, M. D.
Results from 340sample, case-control study.
Methylation DNA markers bound to CA 19-in plasma
9. realize the intersection
The validation sensitivity of the first stage was 79%, the second stage was 82%, the third stage was 94%, the fourth stage was 99%, and the pancreatic catheter adenocarcinoma (PDAC)
The specificity is 92% (81-100%).
This combination is significantly better than CA 19-9 alone.
As Majumder wrote in the summary, "CA 19-
Early detection is unreliable and may be normal in advanced diseases.
"In this sample set, statistical modeling is used to determine the best algorithm for predicting disease status.
Subsequently, the panel was cross-validated by randomly dividing the entire data set into a training set and a test set.
The model of training set fitting is used to predict the disease status of the test set in multiple iterations.
This study uses a small amount of archived patient blood samples, which may lead to excessive
Suitable for this particular sample set and resulting in a subsequent decrease in sensitivity and specificity of the larger expected population.
The Mayo Clinic is currently conducting a prospective validation study.
"After more than a decade of collaboration with precision Science, researchers at the Mayo Clinic continue to provide promising data, in this case, on blood
Biomarkers based on pancreatic cancer testing, "said Dr. Paul Limburg, chief medical officer of precision science and gastrologist at Mayo Clinic, MPH, AGAF.
I "while it is necessary to complete further research, this is an early indicator of encouraging news in the fight against this deadly disease.
"The collaboration between Precision Science and the Mayo Clinic focuses on identifying biomarkers for the 15 most deadly cancers.
Posters of Mayo Clinic researchers treating esophageal cancer will also be displayed on DDW.
About Precision Science
Precision Science
It is a molecular diagnostic company focusing on early detection and prevention of some of the most deadly cancers.
The company has the right to protect its non-
Invasive molecular screening techniques for detecting colorectal cancer.
For more information, please visit the company website atexactscience.
Com, focus on precision science on Twitter @ exactscience, or find precision science on Facebook.
In August 2014, the FDA approved the study on Cologne, the results from the expected 90-site, point-in-time, 10,000-
In March 2014, the New England Journal of Medicine published a key patient trial.
Cologne is included in the American Cancer Association (2018)
Guidelines for colorectal cancer screening and advice from the United StatesS.
Task Force on Preventive services (2016)
National Comprehensive Cancer Network (2016).
Gulongshui was used to screen adults aged 50 or over who had an average risk of colorectal cancer.
Cologne is not suitable for everyone and is not a substitute for diagnostic colonoscopy or monitoring colonoscopy
Individuals at risk, including patients with a history of colorectal and advanced tumors, a family history of colorectal cancer, IBD, or some genetic syndrome.
False positives and false negatives do occur.
Diagnostic colonoscopy should be followed for any positive examination results.
After a negative result occurs, the patient should continue to participate in the screening program at intervals appropriate for a single patient.
The performance of Cologne for repeated testing has not been evaluated or determined.
Medical insurance and most major insurance companies cover Cologne.
For more information about Cologne, please visit the Cologne test. com Rx Only. Forward-
This press release contains a forward-looking statement.
The revised article 27A of the Securities Act of 1933 and the revised outlook statement within the meaning of article 21E of the Securities Trading Act of 1934, this is covered by the "safe harbor" created by these sections. Forward-
Forward-looking statements based on certain assumptions and describing our future plans, strategies and expectations can often be identified by using forward-looking statements
Looks like the term "believe", "expect", "possible", "will", "should", "will", "possible", "seek", "intention", etc. plans, goals, projects, estimates, expectations, or other similar terms.
In addition to the historical factual statements contained in this press release about our strategy, prospects, financial position, operations, costs, plans and objectives, all statements are forward --
Look at the report.
Example of forwarding-
The outlook statement includes, among other things, the expected results of our expected future operations, the expected results of our sales and marketing efforts, the expectations of reimbursement to the payer and the expected results of our product development effortsForward-
Forward-looking statements are neither historical facts nor guarantees of future performance.
Instead, they are only based on our current beliefs, expectations and assumptions about the future of our business, future plans and strategies, forecasts, expected events and trends, the economy and other future conditions.
Because forwarding
Forward-looking statements relate to the future, and they are affected by inherent uncertainties, risks, and environmental changes that are difficult to predict, many of which are beyond our control.
Our actual results and financial position may be significantly different from what is shown in the forward Report
Look at the report.
So you should not rely on any of these advances-
Look at the report.
Important factors that may lead to significant differences between our actual results and financial position and those noted in the forward Report
Forward-looking statements include, among other things, the following: our ability to successfully and profitably market our products and services;
Patients and healthcare providers receive our products and services;
Our ability to meet the needs of our products and services;
Health insurance companies and other payers are willing to provide insurance for our products and services and provide us with appropriate compensation for these products and services;
Number and nature of competition with other cancer screening and diagnostic products and services;
Adopt, modify or repeal the effect of any law, rule, order, interpretation or policy relating to the health care system, including but not limited to any judicial result, administrative or legislative action;
The impact of changes in the price, coverage and reimbursement of our products and services, including but not limited to the results of the protection of access to medical insurance Act of 2014;
Suggestions, guidelines and quality indicators issued by various organizations such as the United StatesS.
The prevention services task force, the American Cancer Society and the National Cancer Screening Quality Assurance Committee or our products and services;
Ability to develop new products and services successfully;
Our ability to effectively leverage strategic partnerships, such as our promotional agreements with Pfizer
And acquisition;
We have successfully established and maintained cooperation, licensing and supplier arrangements;
We maintain the capacity of regulatory approvals and compliance with applicable regulations;
And risk factors and other risks and uncertainties described in Management's Discussion and Analysis of Financial Position and operational results
K and we subsequently submitted quarterly reports on Form 10Q.
We have no obligation to update any forwarding publicly.
Both written and oral forward-looking statements, whether due to new information, future developments or other reasons, may be made from time to time.
About Digestive Disease Week®(DDW)
It is the largest international gathering of doctors, researchers and scholars in the fields of digestive medicine, liver disease, endoscope and stomach surgery.
Jointly sponsored by the American Association for liver disease research (AASLD)
American Association of GI (AGA)
American Institute of digestive endoscopy (ASGE)
And the Society of digestive tract surgery (SSAT)
DDW will be held on May 18
2019 San Diego Convention Center.
The meeting presented more than 5,000 summaries and hundreds of lectures on the latest developments in GI research, medicine and technology.
More information can be found on www. ddw. org.
Media Contact: Carla ConnellyExact technology.
Cconnelly @ exactscience. com 614-302-
5622 Investor Contact: Megan Jones precision science
Meganjones @ exactsciencecom 608-535-
Mayo Clinic and Dr. 8815i
Limburg is relevant to the technology mentioned in this press release.
The Mayo Clinic will use any income it receives to support its failurefor-
Profit mission for patient care, education and research.